0
₹0 0
Nextgen Biotech

Call us:

menu

Eporise 4000iu - Erythropoietin Injection

  • Home
  • Eporise 4000iu - Erythropoietin Injection

Eporise 4000iu - Erythropoietin Injection

Eporise 4000 IU is a synthetic form of erythropoietin used to treat anemia caused by chronic kidney disease, chemotherapy, or HIV treatment. It stimulates red blood cell production in the bone marrow.

Select the packing Size:

Choose Quantity:

-
+
+ Add To Cart
Add to wishlist
Share
Description Product Details
General Information:
Generic Name: Recombinant Human Erythropoietin
Brand Name: Eporise
Packing: Pre-filled syringe or vial
Strength: 4000 IU per dose
Manufacturer: Emcure Pharmaceuticals Ltd.
Form: Injection
Category: Hematopoietic agent, Anti-anemic drug
Product Intro:
Eporise 4000 IU, manufactured by Emcure Pharmaceuticals, is a recombinant human erythropoietin (rHuEPO) injection used to treat anemia. It helps reduce the need for blood transfusions by promoting red blood cell (RBC) formation in patients with kidney failure, cancer, or those undergoing major surgeries.
Uses:
  1. Anemia due to chronic kidney disease (CKD) – in dialysis and non-dialysis patients
  2. Chemotherapy-induced anemia in cancer patients
  3. Anemia related to HIV therapy (especially zidovudine)
  4. Preoperative anemia before major elective surgery
  5. Reducing need for blood transfusions in surgical patients
  6. Anemia in premature infants (off-label in some cases)
Storage Instructions:
  1. Store at 2°C to 8°C (refrigerator)
  2. Do not freeze
  3. Protect from light
  4. Keep out of reach of children
How it Works (Mechanism of Action):
Eporise contains recombinant erythropoietin, a glycoprotein hormone that stimulates erythropoiesis (RBC production). It acts on erythroid progenitor cells in the bone marrow by:
  1. Binding to erythropoietin receptors
  2. Stimulating differentiation and proliferation of red blood cell precursors
  3. Increasing hemoglobin and hematocrit levels
Side Effects:
Common Side Effects:
  1. Headache
  2. Fever
  3. Joint or muscle pain
  4. Nausea or vomiting
  5. Injection site reactions
  6. Fatigue
Severe Side Effects:
  1. High blood pressure
  2. Blood clots (deep vein thrombosis, pulmonary embolism)
  3. Seizures
  4. Pure red cell aplasia (PRCA) – very rare
  5. Allergic reactions (rash, swelling, difficulty breathing)
Dosage (Typical Recommended Dose):
  1. CKD patients (dialysis): 50–100 IU/kg, 3 times weekly
  2. Non-dialysis CKD: 75–150 IU/kg weekly or biweekly
  3. Cancer-related anemia: 150 IU/kg 3 times per week or 40,000 IU weekly
  4. Dose depends on hemoglobin levels, response, and clinical condition
  5. Adjustments are made gradually every 2-4 weeks based on lab results
Method of Administration:
  1. Given as subcutaneous (SC) or intravenous (IV) injection
  2. Administered by healthcare provider or trained caregiver
  3. Rotate injection sites to prevent irritation
  4. Do not shake the syringe or vial
Precautions:
  1. Monitor hemoglobin levels regularly
  2. Avoid if hemoglobin exceeds 12 g/dL to reduce risk of thrombosis
  3. Use with caution in patients with hypertension, cardiovascular disease, seizures
  4. Not recommended in patients with uncontrolled hypertension
  5. May increase tumor progression in some cancers
Drug Interactions:
  1. No significant drug interactions reported
  2. May interact with drugs affecting iron metabolism – iron supplementation may be required
  3. Use with caution alongside immunosuppressants
Allergies:
  1. Contraindicated in individuals with:
    1. Hypersensitivity to erythropoietin or formulation components
    2. History of PRCA after prior EPO therapy
  2. Watch for allergic signs like rash, swelling, and difficulty breathing
Overdose Information:
  1. Overdose may lead to polycythemia (excess red cells), hypertension, and blood clots
  2. Requires reduction or discontinuation of dose and supportive care
  3. No specific antidote – monitor hemoglobin and hematocrit closely
Missed Dose Instructions:
  1. Administer the missed dose as soon as possible
  2. Do not double dose to compensate
  3. Resume regular schedule afterward
Additional Notes:
  1. Iron status should be assessed; iron, folate, and B12 supplementation may be necessary
  2. Periodic monitoring of hemoglobin, blood pressure, and electrolytes is essential
  3. Patients should be educated on recognizing signs of blood clots and high blood pressure
  4. Use during pregnancy only if clearly needed; avoid during breastfeeding unless directed

In The Same Category

Cart